Page 1

November 11 , 2021 Vyant Bio Reports Third Quarter 2021 Results and Provides Strategic Business Updates Strategic Highlights ■ Hired Robert Fremeau , Jr. , PhD as Chief Scientific Officer to lead Vyant Bio's R & D programs targeting the identification of novel therapeutics ■ Entered into two new first phase feasibility programs with leading biopharma companies to demonstrate Vyant Bio's human - derived discovery platform technology for identifying novel biological targets and novel compounds ■ Completed a second large screening of artificial intelligence ( " AI " ) -generated novel compounds for Rett Syndrome , in conjunction with its collaboration partner Atomwise , yielding promising results , including further hit expansion across two unique biological targets and several novel compounds ■ Entered into a collaboration agreement with Cyclica , combining Vyant Bio's patient derived complex organoid biology alongside Cyclica's proteome - wide , Al - enabled discovery platform to identify new treatments for CDKL5 Deficiency Disorder ( " CDD " ) ■ Cash position at September 30 , 2021 was $ 23.2 million CHERRY HILL , N.J. , Nov. 11 , 2021 ( GLOBE NEWSWIRE ) -- Vyant Bio , Inc. ( " Vyant Bio ” , " Company " ) ( Nasdaq : VYNT ) , an emerging global drug discovery company , is rapidly identifying small and large molecule therapeutics to treat central nervous system ( CNS ) and oncology - related diseases . With leading - edge capabilities in data science , biological and chemical sciences , engineering , and regulatory affairs , Vyant Bio capitalizes on in silico , human cell - derived in vitro disease models , and in vivo discovery technologies to identify novel biological targets and valuable therapeutics for patients . Today , Vyant Bio reports its Third Quarter 2021 strategic and business updates in a conference call scheduled for 4.30pm ET . " We are pleased with the progress our R & D team is making to further our CNS rare disease and oncology related HER2 + drug discovery programs , " stated Jay Roberts , CEO of Vyant Bio . The timing of Dr. Robert Fremeau's arrival as our Chief Scientific Officer coincides well with our acceleration to later - stage drug discovery . Dr. Fremeau's extensive experience with scientific research and drug discovery will be invaluable to us as we complete feasibility programs with leading biopharma companies , and develop our preclinical and translational strategy for driving a portfolio of therapeutic candidates from early discovery to human proof of - concept " . " Vyant Bio is committed to transforming the way drugs are discovered by quickly adapting to exciting new technologies and combining our internal capabilities in ways that leverage the